Menopause and Dry Eyes: What the Evidence Actually Shows About HRT, Your Medications, and What to Do Next
Separate the eye exam from the HRT decision
Find My HRT Path organizes your menopause symptoms, treatment preferences, risk history, insurance or cash-pay situation, and state—while this page keeps the eye-care decision with an eye-care clinician.
Menopause and dry eyes are connected, but menopause is not a diagnosis and HRT is not an approved dry-eye treatment. A 25,665-woman cohort found dry eye more often among hormone-therapy users, while small trials conflict. The practical move is an in-person eye exam, a medication review, and a separate HRT decision.
That last sentence probably was not what you expected. Stay with us, because the full picture is more useful than the headline — and there is a second explanation, sitting in a lot of women's medicine cabinets, that almost nobody checks.
Is this page for you?
Best for you if your eyes turned dry, gritty, watery, tired, blurry, or unreliable in your 40s or 50s, and you want to know whether hormones are part of it and what to do next.
Not for you if you are comparing HRT providers on price, medication options, or coverage. That is a different decision — start with our online HRT provider comparison.
Stop reading and get urgent eye care if you have sudden vision loss, sudden double vision, severe eye pain, a painful red eye, marked light sensitivity, a curtain or shadow over your vision, new flashes with a burst of floaters, an eye injury, or one eye suddenly bulging. Do not treat those as ordinary dry eye. After a chemical splash, rinse the eye immediately with clean lukewarm water and seek urgent help.
What should you do next?
| Your situation | Your next step |
|---|---|
| Mild burning or grittiness, worse with screens, wind, fans, or air conditioning. No red flags. | Try preservative-free artificial tears, redirect the airflow, and watch the pattern for one week. |
| It keeps going, gets worse, blurs your vision, makes contacts hurt, or makes you need drops repeatedly every day. | Book an in-person eye exam with an optometrist or ophthalmologist. |
| Your eyes changed after a new prescription, dose change, over-the-counter medicine, or supplement. | Bring the full list and start dates to the prescriber or pharmacist. Do not stop a prescribed medicine on your own. |
| Dry eyes and a persistently dry mouth, with or without fatigue or joint pain. | Say both symptoms out loud to a clinician. This combination deserves a broader evaluation. |
| Sudden vision change, real pain, marked redness, light sensitivity, injury, chemical splash, or discharge. | Urgent eye care today. For a chemical splash, rinse first. |
Urgent-symptom sources: American Academy of Ophthalmology eye-symptom guidance and National Eye Institute retinal-detachment guidance.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
Why trust this page: We read the current FDA prescribing label instead of copying a drug-summary page. We opened the 25,665-woman study that is repeatedly misnamed online. We checked the randomized-trial meta-analysis, the current dry-eye definition, the standard menopause symptom scales, official provider pages, and every drug label used in the treatment table. What we could not verify is stated near the bottom.
Are menopause and dry eyes actually connected?
Yes — the association is real, but the prevalence numbers are easy to misuse. Midlife and postmenopausal women report dry-eye symptoms frequently, and several datasets show more symptoms after menopause. Most of the headline percentages, however, come from questionnaires or clinic populations, not general-population eye examinations that establish dry eye disease.
Here is what happens when you line up the studies. They do not produce one clean percentage, and the reason matters.
| Figure | Who was studied | How it was measured | What it can and cannot say |
|---|---|---|---|
| 57.38% menopausal vs 53.22% premenopausal | 3,547 women in Argentina; median age 52 | Ocular Surface Disease Index (OSDI) questionnaire | Presented at The Menopause Society's 2025 annual meeting. It is a conference abstract, not a peer-reviewed full paper, and it used a symptom questionnaire rather than a complete eye examination. |
| 64.9% overall; 61.7% perimenopausal and 68.2% postmenopausal | 262 women aged 41–60 at a Thai gynecology and menopause clinic; data collected in 2024 and published in 2025 | OSDI questionnaire | Useful for showing how common symptoms were in that clinic. It is not a population estimate, and the peri/post difference was not a dramatic divide. |
| 79% overall; 76.4% perimenopausal and 80.5% postmenopausal; 37.7% severe | 1,947 women aged 45–79 | OSDI questionnaire; mean score 29.2 | Shows a heavy symptom burden in the studied group. Symptom severity rose with age and was lower when menopause occurred later, but the cross-sectional design cannot prove how one woman's symptoms will change over time. |
Sources: The Menopause Society 2025 conference abstracts, the 2025 Thai study, and the 1,947-woman OSDI study.
Here is the catch nobody prints. These figures are mainly questionnaire-defined symptoms in selected groups. The current TFOS DEWS III definition describes dry eye as a symptomatic disease involving loss of tear-film homeostasis, and diagnosis still requires objective evidence that the tear film or ocular surface is not functioning normally. A symptom score alone is not the same thing as an examination-confirmed diagnosis.
So none of those numbers honestly means “X% of all menopausal women have dry eye disease.” What they do support is narrower and still worth knowing: dry-eye symptoms are extremely common in the midlife groups studied, and several datasets report more symptoms after menopause than before it.
OSDI means Ocular Surface Disease Index. It is a validated questionnaire that measures how much eye symptoms and vision-related tasks bother you. It records what you experience; it does not replace an eye examination.
Why do my eyes water if they are supposed to be dry?
Watering and dryness are not opposites. When the surface of the eye is irritated, it can trigger reflex tearing. Those extra tears may overflow without rebuilding a stable tear film, so your eyes can stream in the wind and still burn, blur, or feel gritty.
We are putting this near the top because it is the thing that makes women think they are imagining it. You tell someone your eyes are dry, then they are streaming down your face, and you feel like a liar.
You are not. Think of it like a dry cough: the reaction does not prove the irritated surface is healthy. It proves something is setting it off.
And here is a detail that surprised us. In the Thai study of 262 midlife women, the most frequently reported complaints included light sensitivity, a gritty sensation, and blurred vision — not only the word “dryness.” If your eyes do not feel dry exactly, but they feel wrong, that is not a reason to dismiss it.
What is actually going wrong in there?
Your tears are not just water. A practical way to picture the tear film is an outer oily layer over a water-and-mucin layer. The oil comes from meibomian glands in the eyelids and slows evaporation. The underlying layer lubricates, spreads across the eye, carries protective proteins, and helps the surface stay optically smooth.
That produces two broad failure patterns:
- Evaporative dry eye: you may produce tears, but they disappear too quickly. Meibomian gland dysfunction is a major driver of this pattern.
- Aqueous-deficient dry eye: the lacrimal system does not produce enough watery tears.
- Mixed dry eye: both processes are present, which is common.
Why does that matter? Because treatment is guided by the pattern, the eyelids, inflammation, medications, contact lenses, and other contributors. You cannot reliably identify all of that from the feeling alone. That is the best reason not to keep buying different drops indefinitely.
What changed in the 2025 dry-eye definition?
TFOS DEWS III did not newly turn a “syndrome” into a disease; TFOS DEWS II already called it dry eye disease. The updated definition made the symptomatic nature of the disease explicit and kept loss of tear-film homeostasis at its core. In practical terms, symptoms matter, but symptoms without objective signs do not automatically prove dry eye — they can also signal another ocular-surface or nerve-related problem that needs a different evaluation.
That cuts both ways. A rushed “the quick test looked fine” should not erase your symptoms. But symptoms alone should not be used to declare that menopause caused them either.
Source: TFOS DEWS III Executive Summary.
Which pattern sounds most like yours?
Symptom patterns can point you toward the right next question; they cannot diagnose the cause. Use this table to decide whether careful self-care, a routine eye appointment, a medication conversation, a broader medical evaluation, or urgent care is the right-sized response.
| Pattern | What it may fit | Reasonable next step | Urgency |
|---|---|---|---|
| Burning or grit, worse with screens, wind, fans, or air conditioning | Unstable tear film; possibly an evaporative pattern | Artificial tears, redirect airflow, full-blink breaks. Exam if it persists. | Routine |
| Itching dominates and tracks with pollen, pets, or seasons | Allergy, possibly alongside dry eye | Ask a clinician or pharmacist before stacking drops. Do not assume every itchy eye is menopause. | Routine |
| Crusting, red lid margins, oily debris, or morning stickiness | Eyelid inflammation or blocked meibomian glands | Warm — not hot — compresses and lid care. Book an exam if it persists. | Routine |
| Contacts become unwearable after years of no trouble | Tear-film instability, lens fit, corneal change, or ocular-surface disease | Reduce wear and get a contact-lens and ocular-surface assessment. | Routine; prompt if painful |
| Blur fluctuates and clears after a full blink | Tear film breaking up between blinks | Lubricate and get examined if it recurs or affects driving or work. | Routine; prompt if it stops clearing |
| Symptoms began after a prescription, dose change, OTC medicine, or supplement | Possible medication contribution | Review the medication and timing with the prescriber or pharmacist. Bring dates. | Routine, but do it |
| Persistent dry eyes plus dry mouth, fatigue, or joint pain | Needs systemic evaluation, not just more drops | Tell a clinician about the full combination explicitly. | Prompt |
| Severe pain, sudden vision change, a painful red eye, light sensitivity, flashes and new floaters, a curtain or shadow, discharge, injury, or chemical splash | Not safe to manage as ordinary dry eye | Urgent or emergency eye care. Rinse a chemical splash immediately. | Urgent |
Menopause may be part of the explanation. It is not permission to stop looking.
Eye symptoms and HRT decisions are two different questions
Persistent eye symptoms belong with an optometrist or ophthalmologist. Urgent symptoms belong with urgent eye care. Neither of those is solved by choosing a hormone provider.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
The tool takes about 90 seconds, requires no email, and is for HRT routing — not for diagnosing your eye.
What does the current FDA estrogen label say about eye problems?
We opened a current oral estradiol prescribing label and read its “Eyes” adverse-reaction section line by line. It lists retinal vascular thrombosis, steepening of corneal curvature, and contact-lens intolerance. Dry eye is not listed in that section, but absence from a label is not proof that hormones can never affect the ocular surface.
| What the label says | What it means in plain language |
|---|---|
| Retinal vascular thrombosis | A clot involving a blood vessel at the back of the eye. This is a serious event. |
| Steepening of corneal curvature | The clear front surface of the eye can change shape. |
| Intolerance to contact lenses | Contact lenses that were previously tolerable may become difficult to wear. |
Source: Estradiol Tablets USP on DailyMed. DailyMed's current version was updated January 1, 2026; the professional prescribing information is marked Rev. D 2/2024.
“My contacts just stopped working”
If that is what brought you here, read the table again.
Contact-lens intolerance and steepening of corneal curvature are both on this label. That does not prove either one caused your problem. It does mean “my contacts suddenly failed” deserves a real lens-fit and ocular-surface assessment instead of an endless search for a better lubricating drop.
The cause could still be tear-film instability, a lens issue, corneal change, eyelid disease, or more than one of those. The label cannot diagnose which one applies to you.
What a label listing does — and does not — prove
An adverse-reaction list records events reported during use. It does not prove that every individual event was caused by the medicine. The reverse is also true: dry eye being absent from this label section is not proof that estrogen never contributes to dry-eye symptoms. It means this label does not establish dry eye as a listed ocular adverse reaction.
That is a narrower and more honest claim than either side of this argument usually makes.
The visual warning most pages skip
The same label's “Visual abnormalities” section directs discontinuing the medication pending examination for sudden partial or complete vision loss, or sudden onset of proptosis, double vision, or migraine. It says the medicine should be permanently discontinued if the examination finds papilledema or retinal vascular lesions.
If that describes you, follow the label: stop the labeled medication pending examination, get same-day medical care, and contact the prescriber now. Do not restart it or make a longer-term decision until the examination has happened. This warning is not a complete list of eye emergencies.
Could a medication be causing or worsening the dryness?
Yes. Systemic medicines are a recognized contributor to dry-eye symptoms, and one drug used off-label for hot flashes has dry eye in its own current label. The practical clue is timing: what started, stopped, or changed in the weeks or months before your eyes changed?
In its 2023 nonhormone-therapy position statement, The Menopause Society included oxybutynin among recommended nonhormonal options for vasomotor symptoms, based on the evidence available. Oxybutynin is also an anticholinergic drug, and dry eyes appear in the current DITROPAN XL adverse-reaction information.
So here is a real scenario. A woman starts oxybutynin for hot flashes. A few months later her eyes are miserable. She searches “menopause and dry eyes.” And every page she finds tells her it is her estrogen.
| Medicine or class | What the evidence supports | What this means for you |
|---|---|---|
| Oxybutynin | Used off-label for hot flashes and on The Menopause Society's evidence-based list; dry eyes appear in the current product adverse-reaction information. | If the timing fits, raise it directly. Do not stop it without the prescriber. |
| SSRIs and SNRIs | Antidepressant use is associated with dry eye in the ocular-surface literature, but the strength of evidence and adverse-effect profile are not identical across every drug. | List the exact medicine, dose, and start date instead of treating the whole class as one risk. |
| Oral antihistamines and other anticholinergic medicines | Recognized contributors to reduced tearing and ocular dryness. | Over-the-counter products often disappear from medication lists. Include them anyway. |
| Menopausal hormone therapy | The evidence is genuinely split: a large cohort found higher odds, while small trials produced mixed objective results. | Keep the eye evaluation and HRT decision separate. Full evidence is below. |
Sources: The Menopause Society's 2023 nonhormone therapy position statement, the DITROPAN XL label on DailyMed, and the TFOS DEWS II iatrogenic dry-eye report.
Why giant “drug lists” can mislead you
International dry-eye reports catalogue medicines with different levels of evidence: some have stronger causal support, while others appear through epidemiologic associations, trial reports, or post-marketing signals. Being on a list is not proof that one medicine caused one person's symptoms.
The useful question is not “Is my medicine somewhere on a 100-item list?” It is: Did my symptoms begin or materially change after this medicine or dose, and is there a clinically reasonable alternative?
Take your full list to the prescriber or pharmacist, including nonprescription medicines, supplements, and the date you started each one. Ask which products can affect tearing, blinking, eyelid glands, or the ocular surface.
Do not stop or change a prescribed medication on your own. Some of these medicines are doing important work, and abrupt discontinuation can create a second problem. The action is a medication review, not a solo decision.
Not sure whether the dates line up? Use the seven-day dry-eye and medication timeline below. It gives you one page to take to the eye appointment or prescriber instead of trying to reconstruct three months from memory.
Are dry eyes and dry mouth together a warning sign?
They are a reason to widen the question. Sjögren's disease is an autoimmune condition that can affect the glands that make tears and saliva. It is far more common in women, and dry eyes plus persistent dry mouth is the symptom pair that deserves to be said out loud rather than quietly filed under menopause.
A 2024 Sjögren's Foundation survey of 3,622 respondents was 97% female, with an average diagnosis age of 49.7. The reported trimmed mean from first symptom to diagnosis was about three years; the median was one year.
Three years. Read that again.
That survey is not a population study and cannot tell you how long diagnosis takes for everyone. It does show why “probably menopause” is not enough when both the eyes and mouth stay dry.
Most people with dry eyes do not have Sjögren's. The point is not that you have an autoimmune disease. The point is that the combination changes what a reasonable clinician should consider.
What to tell them:
- How long both your eyes and mouth have been dry
- Whether you need water to swallow dry food
- New cavities, mouth sores, or oral thrush
- Fatigue, joint pain, or muscle pain
- Any autoimmune diagnosis in you or a close relative
- Your complete prescription, OTC, and supplement list
What not to do: do not order one antibody panel online and treat the result as a diagnosis or a clearance. NIAMS states that there is no single test for Sjögren's; diagnosis can involve symptoms, examination, tear and saliva testing, blood work, and sometimes imaging or biopsy.
Sources: NIAMS: Sjögren's disease diagnosis and treatment and the Sjögren's Foundation 2024 patient survey.
A rule that applies to all of this
Dryness that does not respond to the right treatment is itself information. If you are using a suitable product correctly and the problem is not moving, widen the question instead of trying a sixth brand.
Does HRT help dry eyes — or make them worse?
HRT is not FDA-approved to treat dry eye and should not be started for that purpose. The evidence conflicts: a large observational cohort found higher odds of dry eye among hormone-therapy users, while a small randomized-trial meta-analysis found better tear production but no clear improvement in tear stability or ocular comfort.
Here are the actual numbers, without forcing them into a cleaner verdict than the evidence can support.
| Evidence | Population and design | Main result | What it cannot prove |
|---|---|---|---|
| Women's Health Study cohort, JAMA 2001 | 25,665 postmenopausal women; observational follow-up | Compared with nonusers, estrogen-alone users had 1.69 times the odds of clinically diagnosed dry eye or severe symptoms; estrogen plus progestogen users had 1.29 times the odds. Each additional three years of use was associated with a further 15% increase. | It cannot prove hormone therapy caused the eye symptoms or predict what will happen to one woman. |
| 2018 meta-analysis of randomized trials | Seven randomized trials; 358 participants total | Schirmer tear-production results improved overall. Tear break-up time and ocular-comfort scores did not show a significant improvement. | The trials were small and highly heterogeneous. They do not support starting HRT as a reliable dry-eye treatment. |
Sources: the Women's Health Study report and the 2018 randomized-trial meta-analysis.
What the 25,665-woman study found
The study was published by Schaumberg and colleagues in JAMA in 2001. Hormone use was recorded at baseline and during follow-up, and dry eye was assessed later.
- Estrogen alone: odds ratio 1.69, with a 95% confidence interval of 1.49–1.91.
- Estrogen plus a progestogen: odds ratio 1.29, with a 95% confidence interval of 1.13–1.48.
- Duration: every additional three years of hormone-therapy use was associated with a further 15% increase.
An odds ratio of 1.69 does not mean 69% of women developed dry eye. It means the odds were about 69% higher in that group than among nonusers. Because the study observed treatment rather than assigning it, the result is an association, not proof of cause.
Two corrections matter here. The cohort came from the Women's Health Study, not the Women's Health Initiative. And the analysed dry-eye group was 25,665 women, not the larger enrollment figure repeatedly copied into secondary articles.
What the randomized trials found
The 2018 analysis pooled seven randomized trials involving 358 postmenopausal patients.
- Tear production improved on the Schirmer test.
- Tear break-up time did not show a significant improvement.
- Ocular comfort did not show a significant improvement.
The test number moved. How the eyes felt did not.
The trials also disagreed sharply with each other, with very high statistical heterogeneity in several pooled outcomes. That is not a clean treatment signal. It is a warning against pretending the evidence gives one universal answer.
What the hormone biology can — and cannot — tell you
Androgen signaling is important to lacrimal and meibomian-gland function. Estrogen effects on the ocular surface appear to vary by tissue, dose, route, and biological context. That is one reason the simple story — “estrogen fell, therefore adding estrogen will fix the eyes” — does not hold up.
The biology does not justify putting estrogen, testosterone, or any non-ophthalmic hormone product in or around your eyes. Testosterone is a Schedule III controlled substance in the United States and requires a prescription; nothing here minimizes that requirement or presents testosterone as a dry-eye treatment (21 CFR § 1308.13).
Hormone-biology source: TFOS DEWS II Sex, Gender, and Hormones report.
Putting it together
| Claim | Evidence status | What the evidence supports | What it does not support | Practical action |
|---|---|---|---|---|
| “HRT reliably improves dry eye.” | Not established | Some small trials found better tear production. | Starting or changing HRT to treat your eyes. | Make the HRT decision on the full menopause picture, not this symptom alone. |
| “HRT always makes dry eye worse.” | Also not established as a universal claim | A large cohort found higher odds, strongest with estrogen alone. | Predicting one person's response or stopping treatment without review. | If the timing fits, document it and bring it to the prescriber. |
| “Low estrogen is the whole explanation.” | Oversimplified | Sex hormones interact with ocular-surface and eyelid-gland biology. | A one-hormone mechanism or a predictable response to adding estrogen back. | Expect a multi-factor evaluation. |
| “Watery eyes rule out dry eye.” | False | Surface irritation can trigger reflex tearing while the tear film remains unstable. | Using watering to dismiss the symptom pattern. | Report the watering as part of the pattern. |
If you are on HRT and your eyes changed, take the timing to your prescriber. Do not adjust the dose or route by yourself. The eye problem has its own evaluation and treatments; the hormone decision has its own benefits, risks, and indications.
The broader hormone decision is covered in HRT benefits and risks, and evidence-based alternatives for vasomotor symptoms are covered in nonhormonal menopause options.
Why are dry eyes missing from standard menopause symptom checklists?
Because the three widely used menopause symptom instruments we checked do not contain a dedicated eye item. That does not prove clinicians never ask about eyes. It does mean a study relying only on those scales would not capture eye changes unless it added an eye-specific measure.
This is the finding we found most quietly infuriating.
| Instrument | Number of items | What it covers | Dedicated eye item? |
|---|---|---|---|
| Menopause Rating Scale | 11 | Vasomotor, heart discomfort, sleep, mood, irritability, anxiety, exhaustion, sexual problems, bladder problems, vaginal dryness, and joint or muscle discomfort | No |
| Greene Climacteric Scale | 21 | Psychological, somatic, vasomotor, and sexual symptoms | No |
| MENQOL | 29 | Vasomotor, psychosocial, physical, and sexual domains | No |
Scale sources: the Menopause Rating Scale methodology paper, the NIH PhenX Greene Climacteric Scale protocol, and the MENQOL instrument description.
A hormone trial using only one of those scales could show that the overall menopause score improved while never asking whether contact lenses became intolerable or whether the eyes began burning at a screen.
That is a structural reason eye outcomes can disappear from menopause research. It does not explain every clinical conversation. But it does explain why “the form never had a line for it” is not just a feeling.
What can I try today for mild dry-eye symptoms?
Start with the right artificial tears, less direct airflow, full blinking, screen breaks, and warm compresses when the eyelid-gland pattern fits. If symptoms persist, repeatedly blur your vision, make contacts painful, or require drops throughout the day, stop cycling through products and book an in-person exam.
Step 1 — Choose the right category of artificial tear
Follow the label and check contact-lens compatibility. If you need artificial tears four or more times a day, preservative-free products are generally preferred because repeated preservative exposure can irritate the ocular surface.
Frequent use is also information. If you need drops all day or relief lasts only minutes, an examination is more useful than another shelf experiment.
Step 2 — Cut evaporation
Point car vents and desk fans away from your face. Use a humidifier when the room is dry. Wear wraparound glasses in wind. Lower the monitor slightly so more of the eye is covered by the upper lid. Take screen breaks and make the blinks complete — screen use commonly turns full blinks into partial ones.
Step 3 — Use warm compresses only when the eyelid pattern fits
If your lid margins are crusted, sticky, or inflamed, gentle warmth and lid care are common first steps. Warm does not mean hot. Do not use a compress that burns the skin, increases pain, or makes redness worse.
Step 4 — Use gels or ointments when longer coverage is needed
Gels and ointments last longer but temporarily blur vision. Night use often makes more sense. Do not drive until the blur has cleared.
Step 5 — Review everything going in or near the eye
That includes contact lenses, eye makeup, lash products, retinoids or creams near the lid margin, prescriptions, OTC medicines, and supplements.
Sources: National Eye Institute dry-eye treatment guidance and American Academy of Ophthalmology lubricant-drop guidance.
Which eye-drop category fits which situation?
| Category | May fit | Main trade-off | When to ask a clinician |
|---|---|---|---|
| Preservative-free artificial tears | Frequent daytime use or sensitivity to preservatives | Often cost more and may come in single-use vials | If you need them repeatedly every day or relief lasts only minutes |
| Preserved artificial tears | Occasional use according to the label | Preservatives can irritate with frequent exposure | If occasional use becomes four or more times daily |
| Lipid-containing tears | Possible evaporative or eyelid-gland pattern | Texture differs; not every formula is compatible with every contact lens | If the lids appear blocked or symptoms persist |
| Gel drops | Longer-lasting relief | Temporary blur or sticky feeling | If blur affects driving or work |
| Ointments | Overnight dryness or morning sticking | More substantial temporary blur | If you wake in pain or continue worsening |
| Allergy drops | Itching-dominant allergy pattern | Some products can worsen dryness; the diagnosis matters | Before combining several eye products |
| Redness-relief drops | Cosmetic redness only; not a dry-eye treatment | Can mask the problem and some can cause rebound redness | Get evaluated rather than depending on them |
Please do not put these in your eyes
We wish this did not need saying. It does.
- Vaginal estrogen cream or any hormone cream not labeled for ophthalmic use
- Essential oils
- Castor oil unless the specific product is sterile and labeled for use in the eye
- Homemade saline or any unsterile mixture
- Face cream, retinoids, or skincare products
- Anything else not labeled for ophthalmic use
The cornea is protective tissue, but it is also transparent, highly innervated, and vulnerable to contamination and chemical injury. Anything placed directly in the eye must be made and labeled for that purpose.
One honest caveat before you spend money: relief from one drop does not prove the cause, and one failed drop does not prove the disease is severe. Dry-eye treatment works best when it matches the mechanism — and that mechanism is identified by an examination, not by trial and error at the pharmacy.
What can an eye doctor prescribe for dry eye?
There are multiple FDA-approved prescription treatments, and they do different jobs. Some target inflammation, one is expected to reduce evaporation, one is a nasal spray that stimulates the tear pathway, one is a short-term steroid for flares, and a 2025 TRPM8 thermoreceptor agonist treats the signs and symptoms of dry eye disease. None is a hormone.
| Treatment | Type | What it targets | Worth knowing |
|---|---|---|---|
| Preservative-free artificial tears | OTC | Lubrication and symptom relief | A common first step; not a diagnosis |
| Warm compresses and lid hygiene | Self-care | Eyelid and meibomian-gland problems | Useful when the lid pattern fits; warmth should be gentle |
| Restasis (cyclosporine 0.05%) and FDA-approved generics | Prescription eye drop | Inflammation-related suppression of tear production | Generic cyclosporine 0.05% products exist; coverage and cost vary |
| Cequa (cyclosporine 0.09%) | Prescription eye drop | Increasing tear production in dry eye | Instillation-site pain was the most common adverse reaction in trials |
| Vevye (cyclosporine 0.1%) | Prescription eye drop | Signs and symptoms of dry eye disease | A nonaqueous, preservative-free cyclosporine solution |
| Xiidra (lifitegrast) | Prescription eye drop | An inflammatory pathway involved in dry eye | Altered taste is a common labeled adverse reaction |
| Miebo (perfluorohexyloctane) | Prescription eye drop | Signs and symptoms of dry eye disease | Forms a tear-surface monolayer expected to reduce evaporation; the exact mechanism is unknown. Pivotal trials enrolled patients with meibomian-gland dysfunction |
| Tyrvaya (varenicline) | Prescription nasal spray | Stimulates the tear pathway through the nose | Sneezing was very common in trials |
| Eysuvis (loteprednol 0.25%) | Prescription steroid eye drop | Short-term treatment of dry-eye signs and symptoms | Limited to short-term use; steroid renewal requires eye examination and pressure monitoring |
| Tryptyr (acoltremon 0.003%) | Prescription eye drop | Signs and symptoms of dry eye disease through TRPM8 thermoreceptor agonism | FDA-approved May 28, 2025. Instillation-site pain occurred in 50% of trial participants |
| Punctal plugs | Office procedure | Keeping more of the tears you produce on the eye | Tiny plugs are placed in tear-drainage openings |
| Heat, expression, or light-based gland treatments | Office procedure | Selected meibomian-gland problems | Benefit, cost, and insurance coverage vary by device and patient |
Current labels checked August 4, 2026: Restasis, Cequa, Vevye, Xiidra, Miebo, Tyrvaya, Eysuvis, and Tryptyr.
The honest note on Tryptyr
In the trials supporting approval, instillation-site pain was reported in 50% of participants. Half. It is a different mechanism and can increase tear production, but new does not mean best for you. That 50% belongs in the decision, not in the fine print after it.
Why Xdemvy is not in that table
Xdemvy is FDA-approved for Demodex blepharitis, a condition involving mites and eyelid inflammation. It may appear in broad ocular-surface roundups, but it is not an FDA-approved dry-eye treatment. Different condition, different indication.
You are not being dramatic for asking about prescription care. The pharmacy shelf is not the full treatment landscape.
Can a video visit diagnose the type of dry eye I have?
Not completely. A video visit can collect history, look for visible external clues, and help with triage. It cannot perform the physical tests used to classify dry eye: slit-lamp examination, ocular-surface staining, tear break-up time, tear-volume testing, or close inspection of the meibomian-gland openings.
That is the whole problem, is it not? You can read this page twice and still cannot see your own tear film.
Our damaging admission, and it is a real one: the affiliate eye-care marketplace we checked is not a substitute for the exam this page recommends. Sesame's current eye-service page centers online video consultations. We could not verify a dependable in-person dry-eye examination inventory from that page on August 4, 2026. A video visit may still be useful for history or triage. But for persistent dry eye, contact-lens intolerance, or recurrent blur, book a local in-person optometrist or ophthalmologist. We would rather lose the click than sell the wrong appointment.
The National Eye Institute describes dry-eye diagnosis as part of a comprehensive eye exam that can include testing how many tears you produce, how quickly they dry, and the condition of the eyelids and ocular surface.
Should I take omega-3 supplements for dry eye?
Do not treat omega-3 as a proven dry-eye therapy. The 535-person, National Eye Institute-funded DREAM trial found that 3,000 mg per day of fish-derived omega-3 was no better than an olive-oil placebo for the signs or symptoms of moderate-to-severe dry eye over 12 months.
This matters because you have almost certainly been told to take fish oil, possibly by a reputable source.
The trial ran across 27 clinical centers. Both groups improved, but the difference between them was not statistically significant. A meaningful symptom improvement occurred in 61% of the omega-3 group and 54% of the placebo group.
No significant difference.
That improvement in both groups does not tell us why each person felt better. It does show why uncontrolled “I took this and improved” stories cannot establish that the supplement caused the change.
The randomized DREAM extension studied people who had taken omega-3 for the first year. Those assigned to stop did not have significantly worse outcomes than those assigned to continue.
Sources: National Eye Institute summary of the DREAM trial and the DREAM randomized withdrawal extension.
This says nothing about whether omega-3 is appropriate for another medical reason. It says something narrower: the best-known large dry-eye trial did not show superiority over placebo. We are not giving you a supplement protocol. That belongs with a clinician who knows your history, medicines, and bleeding risk.
Does vaginal estrogen help dry eyes?
No. Vaginal estrogen is not approved for eye use and must never be put in or around the eye. Vaginal estrogen products are manufactured and labeled for vaginal or vulvar use, not as sterile ophthalmic preparations. Dry eye is not an FDA-approved indication.
It is a reasonable question. If local estrogen helps estrogen-responsive vaginal tissue, why would it not help the eye?
Because the tissues, delivery requirements, and main dry-eye mechanisms are different. A vaginal cream does not become an eye medicine because both symptoms appeared during menopause. Putting a non-ophthalmic cream on the eye adds contamination and injury risk without an established dry-eye benefit.
Keep those as separate decisions. The complete local-treatment discussion is on our vaginal estrogen guide.
Will dry eyes from menopause go away on their own?
Do not count on persistent dry eye disappearing without treatment. Dry eye can be chronic, and the 1,947-woman cross-sectional study found more severe symptoms at older ages. But that study did not follow the same women through time, so it cannot prove that every woman's dry eye inevitably progresses after menopause.
That distinction matters. “It might persist” is supported. “It will definitely get worse because you are further past menopause” is not.
There is still a practical reason not to wait for years. Severe untreated dry eye can damage the cornea. Recurrent blur, pain, worsening contact-lens intolerance, or symptoms that keep returning deserve proper diagnosis and treatment rather than permanent management from the drugstore aisle.
What kind of doctor should I see for menopause-related dry eyes?
Start with an in-person optometrist for most persistent dry-eye symptoms. An optometrist can examine the lids and ocular surface, measure tear quantity and stability, diagnose most dry-eye disease, and prescribe treatment within the clinician's state scope. An ophthalmologist is the right route for severe disease, complications, diagnostic uncertainty, or surgical and advanced care.
| Who | What they do here | When they are the right call |
|---|---|---|
| Optometrist | Examines the ocular surface and lids, measures tear quantity and stability, assesses contact lenses, diagnoses and manages most dry eye | Your default first appointment for persistent non-emergency symptoms |
| Ophthalmologist | Provides medical and surgical eye care, including advanced evaluation and treatment | Severe disease, corneal damage, complications, uncertain diagnosis, or referral |
| Menopause clinician or current prescriber | Reviews the whole symptom picture, medication timing, and the HRT decision | When your eyes are one of several things that changed or the timing overlaps a treatment change |
| Primary care clinician, dentist, or rheumatology | Helps evaluate systemic causes and the dry-eye/dry-mouth combination | Persistent dry mouth, fatigue, joint symptoms, dental changes, or autoimmune concern |
What should I bring to the appointment?
Bring one week of symptom timing plus the start dates of every prescription, OTC medicine, supplement, HRT change, contact-lens change, and eyelid product. A timeline is harder to dismiss and easier to act on than “my eyes have been bad lately.”
Seven-day dry-eye and medication timeline
| Day and time | Symptoms and severity 0–10 | Screen, wind, fan, or AC exposure | Contact-lens hours | Drops used and frequency | Dry mouth, fatigue, or joint pain | Medication, supplement, skin product, or HRT timing | Any red flag |
|---|---|---|---|---|---|---|---|
| Day 1 | |||||||
| Day 2 | |||||||
| Day 3 | |||||||
| Day 4 | |||||||
| Day 5 | |||||||
| Day 6 | |||||||
| Day 7 |
Also note:
- Which eye is affected, or whether both are
- Whether blur clears after a full blink
- Morning sticking, crusting, or lid redness
- Pain, light sensitivity, discharge, flashes, floaters, or sudden change
- The exact date a medicine, supplement, skincare product, contact lens, or hormone dose changed
How to raise it without being brushed off
Try this exact framing:
“My eyes changed at the same time as these other things. I want to know whether this is the ocular surface, a medication effect, a contact-lens problem, or something systemic — not just which drop to buy.”
That sentence gives a timeline, names the decision, and makes clear that you are asking for an evaluation rather than reassurance.
When does a menopause appointment belong in the plan?
When the eyes are one of several things that changed — sleep, hot flashes, mood, joints, vaginal symptoms, and now this — a menopause clinician can review the whole history and the medication list. That is a different appointment from the eye exam, and you may reasonably need both.
We verified the current published Midi facts below because the CTA belongs only after that distinction is clear.
| Decision fact | Provider-stated information | What we verified | Practical meaning |
|---|---|---|---|
| Care model | Virtual visits with clinicians focused on midlife women's health | Midi describes virtual face-to-face care and full-history review | This can handle the menopause and medication conversation, but it does not replace an in-person eye exam |
| Availability | Offered in all 50 states | Published on Midi's current care page | Confirm appointment availability for your state and time zone before booking |
| Self-pay visit price | $250 initial visit; $150 continued-care visit | Published on Midi's current page on August 4, 2026 | These are visit prices. Confirm medication, laboratory, and other external costs during intake |
| Commercial insurance | In network with most PPO plans | Midi states that coverage varies and copays, coinsurance, and deductibles may apply | Use the coverage checker; “accepts insurance” is not a guarantee of your benefit |
| Medicaid and Medi-Cal | Not participating | Midi states it cannot treat Medicaid or Medi-Cal patients, including as self-pay | This is a hard fit limitation |
| Medicare | Not covered by Medicare or Medicare-related plans | Medicare beneficiaries may self-pay but cannot submit Midi-related claims | Compare the full out-of-pocket path before booking |
Primary source: Midi's current perimenopause-care and pricing page, checked August 4, 2026.
Damaging admission: Midi cannot examine your cornea, stain the ocular surface, measure tear break-up time, or assess your eyelid glands through the screen. If the eye symptom is the only problem, book the eye exam instead. But when several menopause symptoms changed together and you need one clinician to review the full medication and hormone picture, that is the job Midi can actually do.
Check Midi's current availability, coverage, and visit cost →
Affiliate disclosure: The HRT Index may earn a commission if you book through this link, at no extra cost to you. Pricing, insurance, and availability were verified from Midi's published page on August 4, 2026 and must be rechecked before publication and monthly thereafter.
Which two routes is this page not sending you to?
First, a video-only eye visit as a substitute for the physical exam. Second, any vaginal, compounded, or systemic hormone product as a treatment to put in or around the eye. Neither route resolves the actual diagnostic problem.
1. A video consult pretending to be the full dry-eye workup
Video can help with history and triage. It cannot perform the ocular-surface tests this page has spent thousands of words explaining. Book in person when symptoms persist, contacts become intolerable, or vision repeatedly blurs.
2. A hormone cream being repurposed as an eye treatment
No vaginal or compounded hormone cream is an FDA-approved ophthalmic drug. Compounded medicines are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing in the same way it reviews approved drugs. FDA-approved and compounded products are not equivalent categories.
Source: FDA: Compounding and FDA — Questions and Answers.
We would rather lose the click than send you somewhere that cannot do the job.
What did we actually verify? {#what-we-actually-verified}
This page is editorial research. It is not medical advice, and it has not been reviewed by a clinician. Here is exactly what we checked.
Read firsthand, with dates
- Current oral estradiol prescribing information on DailyMed, read August 4, 2026: set ID
f6cb38ab-fdff-9c07-e053-6294a90ad59a; current DailyMed version updated January 1, 2026; professional label marked Rev. D 2/2024. - Women's Health Study dry-eye report, PubMed PMID 11694152: analysed group, hormone categories, odds ratios, confidence intervals, and duration association.
- 2018 meta-analysis of seven randomized trials, 358 participants: Schirmer, tear break-up time, comfort outcomes, and heterogeneity.
- TFOS DEWS III Executive Summary: current definition and diagnostic framing.
- The Menopause Society 2025 conference abstract: 3,547-woman OSDI dataset, explicitly treated here as a conference abstract rather than a peer-reviewed full paper.
- The 2025 Thai study and the 1,947-woman study: sample, measurement method, prevalence, and study-design limits.
- NIAMS Sjögren's guidance and the Sjögren's Foundation 2024 patient survey: no single diagnostic test, respondent profile, and reported diagnostic interval.
- Current FDA/DailyMed labels for dry-eye prescriptions: Restasis, Cequa, Vevye, Xiidra, Miebo, Tyrvaya, Eysuvis, Tryptyr, and Xdemvy's separate Demodex indication.
- DREAM and DREAM extension: dose, sample, comparator, primary result, and withdrawal result.
- Current official pages for Find My HRT Path, Midi, Sesame, and The HRT Index's affiliate disclosure, checked August 4, 2026.
Claims we deliberately did not overstate
- The combined “38 million Americans / fewer than 10% on prescription treatment” statistic is excluded because we could not verify that exact combined claim from a suitable primary source.
- The “171 drugs, only 48 causative” split is excluded because the available classifications did not support that precise contrast strongly enough for this page.
- The 2025 conference percentage is labeled as questionnaire-defined symptom data, not examination-confirmed disease.
- TFOS DEWS III is described as an updated definition, not as the moment dry eye first became a disease rather than a syndrome.
- Sesame is not presented as a dependable route to an in-person dry-eye examination; the eye-service page we verified centers video visits.
- Find My HRT Path is described only as an HRT routing tool. The printable medication timeline is part of this article, not a promised quiz feature.
- An adverse-reaction label entry — or its absence — is not treated as proof of a specific HRT effect in one person.
How The HRT Index works
Our provider assessments follow The HRT Index Verification Standard — we read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule. We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We never publish a numeric provider score.
Corrections: If you find an error, contact us. We will correct it and date the correction.
Frequently asked questions
Can menopause cause dry eyes?
Yes. Dry-eye symptoms are commonly reported in midlife and several datasets show more symptoms after menopause. But menopause is one contributor among many; symptoms can also reflect eyelid-gland dysfunction, medications, contact lenses, allergy, autoimmune disease, or another ocular-surface problem.
Does HRT help dry eyes?
HRT is not approved to treat dry eye. Small randomized trials found an improvement in one tear-production measure but not in tear stability or ocular comfort, while a large observational cohort found higher odds of dry eye among hormone-therapy users. Do not start HRT for your eyes.
Can HRT cause dry eyes?
A cohort of 25,665 women found higher odds of dry eye among hormone-therapy users: 1.69 for estrogen alone and 1.29 for estrogen plus a progestogen. That is an association, not proof that HRT caused one person's symptoms. If the timing fits, take it to the prescriber rather than changing treatment yourself.
Why do my eyes water if they are dry?
Surface irritation can trigger reflex tearing. The tears may overflow without restoring a stable tear film, so watering can happen alongside burning, grittiness, or fluctuating blur.
Are dry eyes and dry mouth together a warning sign?
They are a reason to tell a clinician about both symptoms. Dry eyes and dry mouth are the main symptom pair in Sjögren's disease, but they can also come from medicines and other conditions. Sjögren's cannot be diagnosed or excluded by one internet checklist or one antibody result.
What is the best eye drop for menopausal dry eyes?
There is no single best drop because the cause and dry-eye subtype differ. If you need artificial tears four or more times daily, preservative-free products are generally preferred. Persistent, recurrent, or vision-blurring symptoms need an exam rather than a brand ranking.
Can dry eyes cause blurry vision?
Yes. An unstable tear film can cause blur that improves after a full blink. Persistent blur, sudden blur, one-sided change, pain, flashes and floaters, or a curtain over the vision needs examination rather than a menopause assumption.
Do dry eyes from menopause go away?
They may fluctuate, but persistent dry eye can be chronic. Cross-sectional data show more severe symptoms at older ages, but those studies do not prove that every woman's symptoms inevitably progress. Treat persistent symptoms rather than waiting for years.
Can I still wear contact lenses?
Often, yes, after the cause is assessed and the lens plan is adjusted. Contact-lens intolerance and steepening of corneal curvature appear in one current oral estradiol label, but a sudden change can also reflect tear-film instability, fit, lens material, or ocular-surface disease.
Does vaginal estrogen help dry eyes?
No. Vaginal estrogen is not an ophthalmic product and is not approved to treat dry eye. Never apply it in or around the eye.
Should I take omega-3 for dry eyes?
The 535-person DREAM trial found 3,000 mg per day no better than an olive-oil placebo for dry-eye signs or symptoms over 12 months. The withdrawal extension also found no significant worsening after discontinuation compared with continuation. Discuss supplements in the context of your full medical history rather than buying them as a proven dry-eye treatment.
What kind of doctor treats menopause-related dry eyes?
Start with an in-person optometrist for most persistent dry-eye symptoms. An ophthalmologist is appropriate for severe disease, complications, uncertainty, or referral. Add the menopause prescriber when several symptoms changed together or the timing overlaps a medication or HRT change.
When are dry-eye symptoms urgent?
Get urgent care for sudden vision loss, severe pain, a painful red eye, marked light sensitivity, new flashes with many floaters, a curtain or shadow over vision, eye injury, chemical exposure, or sudden double vision. Rinse a chemical splash immediately with clean lukewarm water while arranging help.
One last thing
If you take nothing else from this page, take this: the eye problem and the hormone question are two separate decisions, and trying to make one solve the other is how women lose a year.
Get the eye examined by someone who can examine it. Take your medication list with dates. Say the dry-mouth part out loud if it applies. Make the HRT decision on its own merits — for the symptoms and indications hormone therapy is actually used to treat.
Still not sure which HRT program is right for you? Take our free, about-90-second matching quiz.
Educational information only. Not medical advice, diagnosis, or treatment. Always speak with a qualified clinician about your situation. The HRT Index earns commissions from some providers linked on this page — see our affiliate disclosure. Compounded medications are not FDA-approved and are never presented here as equivalent to FDA-approved medication.